Madisch A, Holtmann G, Plein K, Hotz J
Medical Department I, Technical University Hospital, Dresden, Germany.
Aliment Pharmacol Ther. 2004 Feb 1;19(3):271-9. doi: 10.1111/j.1365-2036.2004.01859.x.
Herbal medications have been used in many countries for the treatment of patients with irritable bowel syndrome. Controlled data supporting the efficacy of these treatments in patients with irritable bowel syndrome are lacking.
To assess the efficacy and safety of a commercially available herbal preparation (STW 5) (nine plant extracts), the research herbal preparation STW 5-II (six plant extracts) and the bitter candytuft mono-extract in patients with irritable bowel syndrome.
Two hundred and eight patients with irritable bowel syndrome were recruited after standardized diagnostic work-up into a double-blind, placebo-controlled, multi-centre trial and were randomly assigned to receive one of four treatments: commercially available herbal preparation STW 5 (n = 51), research herbal preparation STW 5-II (n = 52), bitter candytuft mono-extract (n = 53) or placebo (n = 52). The main outcome variables were the changes in total abdominal pain and irritable bowel syndrome symptom scores.
Two hundred and three patients completed the trial. STW 5 and STW 5-II were significantly better than placebo in reducing the total abdominal pain score (intention-to-treat: STW 5, P = 0.0009; STW 5-II, P = 0.0005) and the irritable bowel syndrome symptom score (intention-to-treat: STW 5, P = 0.001; STW 5-II, P = 0.0003) at 4 weeks. There were no statistically significant differences between the bitter candytuft mono-extract group and the placebo group (P = 0.1473, P = 0.1207).
The commercially available herbal preparation STW 5 and its research preparation STW 5-II are both effective in alleviating irritable bowel syndrome symptoms.
草药制剂在许多国家已被用于治疗肠易激综合征患者。目前缺乏支持这些治疗方法对肠易激综合征患者疗效的对照数据。
评估一种市售草药制剂(STW 5)(九种植物提取物)、研究用草药制剂STW 5-II(六种植物提取物)和白鲜单提取物对肠易激综合征患者的疗效和安全性。
208例肠易激综合征患者在经过标准化诊断检查后被纳入一项双盲、安慰剂对照、多中心试验,并随机分配接受四种治疗之一:市售草药制剂STW 5(n = 51)、研究用草药制剂STW 5-II(n = 52)、白鲜单提取物(n = 53)或安慰剂(n = 52)。主要结局变量为全腹痛和肠易激综合征症状评分的变化。
203例患者完成了试验。在4周时,STW 5和STW 5-II在降低全腹痛评分(意向性分析:STW 5,P = 0.0009;STW 5-II,P = 0.0005)和肠易激综合征症状评分(意向性分析:STW 5,P = 0.001;STW 5-II,P = 0.0003)方面显著优于安慰剂。白鲜单提取物组与安慰剂组之间无统计学显著差异(P = 0.1473,P = 0.1207)。
市售草药制剂STW 5及其研究制剂STW 5-II均能有效缓解肠易激综合征症状。